Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Feb 22, 2023 11:18am
183 Views
Post# 35298348

Long acting injectable

Long acting injectable

"Turning to emerging technologies, Dr Fauci envisions the renaissance of broadly neutralizing antibodies (bnAb) for pre-exposure prophylaxis (PrEP). Despite sobering AMP trial outcomes, which tested single bnAbs, Dr Fauci pointed out that “we have to do with bnAbs what we did for ART – combine them”.  bnAb combinations could further expand the options for long-acting therapies by simultaneously targeting different epitopes on the HIV envelope or be used together with other long-acting injectables."

 

https://www.linkedin.com/posts/lifescience-dynamics-limited_hiv-hivprevention-croi2023-activity-7033499554805116930-cclT?utm_source=share&utm_medium=member_ios

 

"Patients went from taking 28 pills per day to one or two, or even a long-acting injectable, all of which reduce viral loads to undetectable levels and allow people with HIV to live near-normal lives."

Dr. Fauci to Young Scientists: Take the Ball and Run With It - Infectious Disease Special Edition

<< Previous
Bullboard Posts
Next >>